By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen-Cilag International NV 

1, rue Camille Desmoulins
TSA 91003
Issy-les-Moulineaux  Cedex  92787  France
Phone: 33-1-5500-4500 Fax: 33-1-5500-2885


SEARCH JOBS


Industry
Biotechnology






Company News
Janssen-Cilag International NV (JNJ) Submits EU Marketing Application For VELCADE® (Bortezomib) In Mantle Cell Lymphoma 6/27/2014 10:24:45 AM
Janssen-Cilag International NV (JNJ) Release: OLYSIO™ (Simeprevir) Receives Marketing Authorization In The European Union For The Treatment Of Adults With Hepatitis C Genotype 1 And 4 Infection 5/16/2014 8:58:39 AM
Janssen-Cilag International NV (JNJ) Release: VOKANAMET® (Canagliflozin And Immediate Release Metformin Hydrochloride Fixed Dose Combination) Approved In The European Union For Treatment Of Adults With Type 2 Diabetes [1] 4/25/2014 9:51:08 AM
Janssen-Cilag International NV (JNJ) Release: VOKANAMET™ (Canagliflozin And Metformin Fixed Dose Combination) Receives Positive CHMP Opinion Recommending Approval In The European Union For The Treatment Of Adults With Type 2 Diabetes[1] 2/21/2014 8:45:33 AM
Janssen-Cilag International NV (JNJ)'s INVOKANA™ Wins Approval In The EU For Type 2 Diabetes Patients 11/22/2013 6:25:43 AM
Janssen-Cilag International NV (JNJ) Release: New Marketing Authorisation Application Submitted to European Medicines Agency for Ibrutinib for the Treatment of Two Forms of Blood Cancer 10/30/2013 7:29:36 AM
Janssen-Cilag International NV (JNJ) Submits Marketing Authorisation Application to European Medicines Agency for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir With Cobicistat 10/15/2013 9:29:02 AM
Janssen-Cilag International NV (JNJ) Release: New and Long-Term Use Results for Canagliflozin to be Presented at European Association for the Study of Diabetes Annual Meeting 9/18/2013 10:09:49 AM
European Commission (EC) Approves Janssen-Cilag International NV (JNJ)'s VELCADE® as a Frontline Induction Therapy Before Stem Cell Transplantation 8/8/2013 6:56:56 AM
CHMP Gives a Positive Opinion for the Use of Janssen-Cilag International NV (JNJ)'s VELCADE® as Retreatment and for Frontline Induction Therapy Before Stem Cell Transplantation 6/28/2013 9:35:09 AM
123
//-->